IncyteCARES and MONJUVI® logo linking back to the hompage

IncyteCARES for MONJUVI is a program for
residents of the United States and Puerto Rico.

For Healthcare Professionals Arrow

We're Here to Support You During Treatment With MONJUVI® (tafasitamab-cxix)

At IncyteCARES for MONJUVI, our team can help you understand your insurance coverage, explore financial
assistance options, and provide as-needed support.

For Enrolled Patients, Our Team Will:

  • Call you to review your insurance coverage for MONJUVI
  • Assess your eligibility for savings or financial assistance programs*
  • Explain additional support and resources available during your treatment

*Terms and conditions apply. Terms of these programs may change at any time.

Financial Assistance, Savings, and Support Options for MONJUVI

Eligible patients can receive MONJUVI for as little as $0, subject to certain limits†

To qualify, you must:

  • Have commercial healthcare coverage. Patients insured under federal or state government healthcare programs— including Medicare Part B, Medicare Advantage, Medicaid, TRICARE, or any state medical or pharmaceutical assistance program—are not eligible. Patients without healthcare coverage are also not eligible
  • Be a resident of the United States or Puerto Rico
  • Have a valid prescription for MONJUVI for an FDA-approved use

†Uninsured, cash-paying, or Alternate Funding Program (AFP) patients are not eligible. Not valid for patients insured through Medicare Part B, Medicare Advantage, Medicaid, TRICARE, or any state medical or pharmaceutical assistance program. Patient enrollment in a copay adjustment program, such as a maximizer or accumulator program, may impact the value of this offer. Annual benefit maximum applies, as may other restrictions. Program benefit applies to medication cost only and does not cover any costs to administer the medication. Valid prescription for MONJUVI® (tafasitamab-cxix) for an FDA-approved indication or compendia-recognized use is required. Please see the full Patient Terms and Conditions or call IncyteCARES for MONJUVI at 1-855-452-5234. Update effective as of May 1, 2024.

†Uninsured, cash-paying, or Alternate Funding Program (AFP) patients are not eligible. Not valid for patients insured through Medicare Part B, Medicare Advantage, Medicaid, TRICARE, or any state medical or pharmaceutical assistance program. Patient enrollment in a copay adjustment program, such as a maximizer or accumulator program, may impact the value of this offer. Annual benefit maximum applies, as may other restrictions. Program benefit applies to medication cost only and does not cover any costs to administer the medication. Valid prescription for MONJUVI® (tafasitamab-cxix) for an FDA-approved indication or compendia-recognized use is required. Please see the full Patient Terms and Conditions or call IncyteCARES for ZYNYZ at 1-855-452-5234. Update effective as of May 1, 2024.

To enroll, you can either:

    1. Call IncyteCARES for MONJUVI at 1-855-452-5234 , Monday through Friday, 8 AM–8 PM ET. A representative will ask a few questions. If you are eligible, we can enroll you in the Savings Program immediately so you can begin receiving MONJUVI for as little as $0 out-of-pocket cost.
    2. Ask your Healthcare Professional to enroll you in the Savings Program.

Eligible patients can receive MONJUVI free of charge‡

The IncyteCARES for MONJUVI Patient Assistance Program (PAP) helps eligible patients who do not have medical insurance or who have trouble affording their out-of-pocket costs for MONJUVI. The program provides free medication, but does not cover the cost to give you your infusion. No purchase contingencies or other obligations apply.

To qualify, you must:

  • Be confirmed as eligible for and enrolled in IncyteCARES for MONJUVI
  • Be a resident of the United States or Puerto Rico
  • Have a valid prescription for MONJUVI for an FDA-approved use
  • Meet one of these 3 criteria:

Uninsured

    1. You have no medical coverage and meet household income criteria

Underinsured§

    1. text
    2. You have Medicare Part B and meet household income criteria
    3. You have any other type of healthcare insurance (commercial, Medicaid, etc) but have exhausted or been denied coverage for MONJUVI and meet household income criteria

To apply, you can either:

    1. Call IncyteCARES for MONJUVI at 1-855-452-5234, Monday through Friday, 8 AM–8 PM ET. 

      To start, we’ll ask you a few questions to help determine your eligibility for this program. If you qualify, we will need to verify your current household income. You have the option to authorize us to perform a credit check or to provide us other evidence of income. It can be documents such as your most recent federal income tax return, 2 recent pay stubs, or your most recent Social Security statement. If you aren’t able to provide income documentation, you may submit a notarized income statement. Once we review your income information, we’ll notify you if you are fully approved for the IncyteCARES for MONJUVI Patient Assistance Program and can receive MONJUVI for free.

    2. Ask your Healthcare Professional to submit an application form for you.

‡Terms and conditions apply. Terms of this program may change at any time.

§Patients who are enrolled in an Alternate Funding Program (AFP) are not eligible to receive free drug.

Patients may be eligible for help with medicine, treatment-related travel, and other costs.

If you do not qualify for our IncyteCARES for MONJUVI Savings or Patient Assistance Programs, we may be able to provide information about other organizations or independent foundations that offer support. If you’re eligible, these independent organizations sometimes provide help with your medicine costs, transportation or lodging expenses related to treatment, or counseling services offered at reduced or no cost. Eligibility and availability
of these programs are determined by the individual organizations.

To learn more:

Call IncyteCARES for MONJUVI at 1-855-452-5234, Monday through Friday, 8 AM–8 PM ET.

Call IncyteCARES for Monjuvi at 1-855-452-5234

Questions?

Call IncyteCARES for MONJUVI at 1-855-452-5234,

Monday through Friday,
8 AM–8 PM ET

WHAT IS MONJUVI?

MONJUVI (tafasitamab-cxix) is a prescription medicine given with lenalidomide to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) that has come back (relapsed) or that did not respond to previous treatment (refractory) and who cannot receive a stem cell transplant.

It is not known if MONJUVI is safe and effective in children.

The approval of MONJUVI is based on a type of response rate. There is an ongoing study to confirm the clinical benefit of MONJUVI.

IMPORTANT SAFETY INFORMATION

Important information I should know, including possible side effects, about MONJUVI:

MONJUVI may cause serious side effects, including infusion-related reactions, low blood cell counts, and infections.

The most common side effects of MONJUVI include feeling tired or weak, diarrhea, cough, fever, swelling of lower legs or hands, respiratory tract infection, and decreased appetite.

These are not all the possible side effects of MONJUVI. Your healthcare provider will give you medicines before each infusion to decrease your chance of infusion reactions. If you do not have any reactions, your healthcare provider may decide that you do not need these medicines with later infusions. Your healthcare provider may need to delay or completely stop treatment with MONJUVI if you have severe side effects.

Before receiving MONJUVI, tell your healthcare provider about all your medical conditions, including if you have an active infection or have had one recently, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. You should not become pregnant or breastfeed during treatment with MONJUVI and should use an effective method of birth control (contraception) and not breastfeed during and for at least 3 months after your last dose of MONJUVI. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with MONJUVI. Refer to the lenalidomide Medication Guide for important information about pregnancy, contraception, and blood and sperm donation.

Tell your healthcare provider about all the medications you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Incyte Medical Information at 1-855-463-3463.

Please see the Full Prescribing Information, including Patient Information, for MONJUVI.

WHAT IS MONJUVI?

MONJUVI (tafasitamab-cxix) is a prescription medicine given with lenalidomide to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) that has come back (relapsed) or that did not respond to previous treatment (refractory) and who cannot receive a stem cell transplant.

It is not known if MONJUVI is safe and effective in children.

The approval of MONJUVI is based on a type of response rate. There is an ongoing study to confirm the clinical benefit of MONJUVI.

IMPORTANT SAFETY INFORMATION

Important information I should know, including possible side effects, about MONJUVI:

MONJUVI may cause serious side effects, including infusion-related reactions, low blood cell counts, and infections.

The most common side effects of MONJUVI include feeling tired or weak, diarrhea, cough, fever, swelling of lower legs or hands, respiratory tract infection, and decreased appetite.

These are not all the possible side effects of MONJUVI. Your healthcare provider will give you medicines before each infusion to decrease your chance of infusion reactions. If you do not have any reactions, your healthcare provider may decide that you do not need these medicines with later infusions. Your healthcare provider may need to delay or completely stop treatment with MONJUVI if you have severe side effects.

Before receiving MONJUVI, tell your healthcare provider about all your medical conditions, including if you have an active infection or have had one recently, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. You should not become pregnant or breastfeed during treatment with MONJUVI and should use an effective method of birth control (contraception) and not breastfeed during and for at least 3 months after your last dose of MONJUVI. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with MONJUVI. Refer to the lenalidomide Medication Guide for important information about pregnancy, contraception, and blood and sperm donation.

Tell your healthcare provider about all the medications you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Incyte Medical Information at 1-855-463-3463.

Please see the Full Prescribing Information, including Patient Information, for MONJUVI.